公开(公告)号：US20130337053A1

公开(公告)日：2013-12-19

申请号：US13918539

申请日：2013-06-14

Applicant: Leo RUBIN ,  Shaker MOUSA ,  Edward MATTES

Inventor： Leo RUBIN ,  Shaker MOUSA ,  Edward MATTES

IPC: A61K38/22 ,  A61K45/06 ,  A61K31/197 ,  A61K9/48

CPC classification number: A61K38/2278 ,  A61K9/48 ,  A61K9/5161 ,  A61K31/197 ,  A61K45/06 ,  B82Y5/00 ,  A61K2300/00

Abstract: A formulation comprising T3/VIP nanoparticles, wherein the T3/VIP nanoparticle comprises both T3 and VIP encapsulated or immobilized on a bioabsorbable polymer. The invention further provides for methods of making a formulation comprising a T3/VIP nanoparticle. The invention further provides for methods of treatment utilizing said T3/VIP nanoparticle.

Abstract translation: 包含T3 / VIP纳米颗粒的制剂，其中所述T3 / VIP纳米颗粒包含包封或固定在生物可吸收聚合物上的T3和VIP。 本发明进一步提供制备包含T3 / VIP纳米颗粒的制剂的方法。 本发明还提供了利用所述T3 / VIP纳米颗粒的治疗方法。

公开(公告)号：US08507723B2

公开(公告)日：2013-08-13

申请号：US13529249

申请日：2012-06-21

Applicant: Shaker Mousa ,  Dahui Liu

Inventor： Shaker Mousa ,  Dahui Liu

IPC: C07C233/05 ,  A61K31/65

CPC classification number: C07C323/63 ,  A61K31/167 ,  C07C219/06 ,  C07C235/20 ,  C07C235/56 ,  C07C235/60 ,  C07C235/62 ,  C07C237/40 ,  C07C237/42 ,  C07C237/44 ,  C07C243/38 ,  C07C279/12 ,  C07C279/14 ,  C07C323/42 ,  C07C2601/14 ,  C07C2603/92 ,  C07D239/28

Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.

公开(公告)号：US08232428B2

公开(公告)日：2012-07-31

申请号：US12720734

申请日：2010-03-10

Applicant: Shaker Mousa ,  Dahui Liu

Inventor： Shaker Mousa ,  Dahui Liu

IPC: C07C233/65 ,  A61K31/165

CPC classification number: C07C323/63 ,  A61K31/167 ,  C07C219/06 ,  C07C235/20 ,  C07C235/56 ,  C07C235/60 ,  C07C235/62 ,  C07C237/40 ,  C07C237/42 ,  C07C237/44 ,  C07C243/38 ,  C07C279/12 ,  C07C279/14 ,  C07C323/42 ,  C07C2601/14 ,  C07C2603/92 ,  C07D239/28

Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.

公开(公告)号：US20060115471A1

公开(公告)日：2006-06-01

申请号：US11343003

申请日：2006-01-30

Applicant: Robert Colman ,  Shaker Mousa

Inventor： Robert Colman ,  Shaker Mousa

IPC: A61K39/395

CPC classification number: C07K16/36 ,  A61K2039/505 ,  C07K2317/73 ,  C07K2317/76

Abstract: Antibodies directed against an antigenic determinant of high molecular weight kininogen domain 5, particularly a determinant located in the region formed by light chain amino acids Gly(440) to Lys(502), inhibit angiogenesis.

Abstract translation: 针对高分子量激肽原结构域5（特别是位于由轻链氨基酸Gly（440）至Lys（502）形成的区域中的决定簇）的抗原决定簇的抗体抑制血管发生。

公开(公告)号：US20050124862A1

公开(公告)日：2005-06-09

申请号：US10943072

申请日：2004-09-15

Applicant: Shaker Mousa ,  Faith Davis ,  Paul Davis

Inventor： Shaker Mousa ,  Faith Davis ,  Paul Davis

IPC: A61B5/00 ,  A61K9/00 ,  A61K31/192 ,  A61K31/195 ,  A61K38/22 ,  A61K45/06 ,  A61K47/48 ,  A61P9/10

CPC classification number: A61K31/198 ,  A61K9/00 ,  A61K9/146 ,  A61K31/192 ,  A61K31/195 ,  A61K38/1825 ,  A61K45/06 ,  A61K47/58 ,  A61K47/60 ,  A61K47/61 ,  A61K2300/00

Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric form of thyroid hormone, or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

Abstract translation: 公开了治疗具有与血管发生相关的病症的受试者的方法，包括施用有效量的甲状腺激素或其拮抗剂的聚合形式，以促进或抑制受试者的血管生成。 还公开了甲状腺激素或甲状腺激素类似物的聚合形式的组合物。

公开(公告)号：US20160151532A1

公开(公告)日：2016-06-02

申请号：US14949715

申请日：2015-11-23

Applicant: Leo RUBIN ,  Shaker MOUSA

Inventor： Leo RUBIN ,  Shaker MOUSA

IPC: A61L15/28 ,  A61L15/44 ,  A61L15/20 ,  A61L15/58 ,  A61L15/64 ,  A61L15/26

CPC classification number: A61L15/28 ,  A61K9/0024 ,  A61K9/1647 ,  A61K9/1652 ,  A61K9/5153 ,  A61K9/5161 ,  A61K9/7007 ,  A61K9/703 ,  A61K31/137 ,  A61K38/2271 ,  A61K47/36 ,  A61L15/20 ,  A61L15/225 ,  A61L15/26 ,  A61L15/44 ,  A61L15/58 ,  A61L15/64 ,  A61L2300/204 ,  A61L2300/252 ,  A61L2300/418 ,  A61L2300/62 ,  A61L2400/04 ,  C08B37/003 ,  C08L5/08

Abstract: Disclosed herein is a novel hemostatic patch that may be used to control and/or arrest bleeding in patients. The patch offers an effective but also minimally invasive way to control and/or arrest bleeding in a patient. The patch comprises a mucoadhesive and a compound that causes vasoconstriction. In a preferred aspect, the patch comprises chitosan and Neuropeptide Y. Also disclosed are methods of using the novel hemostatic patch.

Abstract translation: 本文公开了一种可用于控制和/或阻止患者出血的新型止血补片。 补片提供有效但也是微创的方式来控制和/或阻止患者的出血。 贴剂包括粘膜粘附和引起血管收缩的化合物。 在优选的方面，贴剂包含壳聚糖和神经肽Y.还公开了使用新型止血贴剂的方法。

公开(公告)号：US08129103B2

公开(公告)日：2012-03-06

申请号：US12109784

申请日：2008-04-25

Applicant: Lakshman R. Sehgal ,  Shaker Mousa

Inventor： Lakshman R. Sehgal ,  Shaker Mousa

IPC: A01N1/02

CPC classification number: A01N1/0215 ,  A01N1/02 ,  A01N1/0226

Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Abstract translation: 本发明涉及用于储存血小板以保持血小板功能和新鲜度的组合物和方法。 更具体地，本发明涉及使用具有抗血小板剂，抗凝血剂和氧载体的防腐剂组合物，以保持血小板的新鲜度。 另外，组合物还可以含有超短效广谱抗微生物剂。 防腐剂组合物可用于将血小板置于液态，冷冻状态或冻干状态。

公开(公告)号：US07964338B2

公开(公告)日：2011-06-21

申请号：US11330132

申请日：2006-01-12

Applicant: Lakshman R. Sehgal ,  Shaker Mousa

Inventor： Lakshman R. Sehgal ,  Shaker Mousa

IPC: A01N1/02

CPC classification number: A01N1/0215 ,  A01N1/02 ,  A01N1/0226

Abstract: The present invention relates to compositions and methods for storing platelets to preserve the function and freshness of the platelets. More particularly, the present invention relates to the use of a preservative composition having an antiplatelet agent, an anticoagulant, and an oxygen carrier, for maintaining the freshness of platelets. Additionally, the composition may also contain an ultra-short acting broad spectrum anti-microbial agents. The preservative composition may be used to store platelets in a liquid state, a frozen state, or a freeze-dried state.

Abstract translation: 本发明涉及用于储存血小板以保持血小板功能和新鲜度的组合物和方法。 更具体地，本发明涉及使用具有抗血小板剂，抗凝血剂和氧载体的防腐剂组合物，以保持血小板的新鲜度。 另外，组合物还可以含有超短效广谱抗微生物剂。 防腐剂组合物可用于将血小板置于液态，冷冻状态或冻干状态。

公开(公告)号：US20110124664A1

公开(公告)日：2011-05-26

申请号：US12971006

申请日：2010-12-17

Applicant: Shaker Mousa ,  Dahui Liu

Inventor： Shaker Mousa ,  Dahui Liu

IPC: A61K31/167 ,  C07C323/42 ,  C07C323/63 ,  C07D403/12 ,  C07C243/38 ,  C07D239/28 ,  C07C69/736 ,  A61K31/24 ,  A61K31/4178 ,  A61K31/505 ,  A61P9/00 ,  A61P1/04 ,  A61P15/08 ,  A61P35/00 ,  A61P19/02 ,  A61P17/06 ,  A61P9/10

CPC classification number: C07C323/63 ,  A61K31/167 ,  C07C219/06 ,  C07C235/20 ,  C07C235/56 ,  C07C235/60 ,  C07C235/62 ,  C07C237/40 ,  C07C237/42 ,  C07C237/44 ,  C07C243/38 ,  C07C279/12 ,  C07C279/14 ,  C07C323/42 ,  C07C2601/14 ,  C07C2603/92 ,  C07D239/28

Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.

Abstract translation: 本发明的方面涉及可用于调节血管发生的化合物和方法以及通过施用聚阳离子化合物治疗或预防与血管生成相关的疾病的方法。 本发明涉及包括动物和人在内的哺乳动物中用于抑制血管发生介导的疾病的使用方法和组合物。 另外，本发明涉及聚阳离子与其它抗血管生成剂的组合使用，用于治疗不同的血管发生介导的病症。 此外，这些聚阳离子化合物可以与各种抗炎和细胞毒剂以及癌症患者中的放射治疗剂一起使用以预防和治疗肿瘤生长和转移。

公开(公告)号：US07741311B2

公开(公告)日：2010-06-22

申请号：US11324702

申请日：2006-01-03

Applicant: Shaker Mousa ,  Robert Linhardt

Inventor： Shaker Mousa ,  Robert Linhardt

IPC: A61K31/70 ,  C07H15/00

CPC classification number: C08K5/41 ,  A61K31/765 ,  A61K47/56 ,  A61K47/60 ,  C07H11/00 ,  C08B37/0021 ,  C08B37/003 ,  C08B37/0045 ,  C08B37/0072 ,  C08H1/04

Abstract: A composition and a method of treating a subject with respect to a pathological condition comprised by the subject. The composition comprises a sulfated saccharide conjugated to a polymer. The method comprises administering to the subject a composition comprising a sulfated saccharide conjugated to a polymer or a sulfated saccharide. The sulfated saccharide has a molecular weight less than 5000 Dalton.

Abstract translation: 相对于受试者包含的病理状况治疗受试者的组合物和方法。 该组合物包含与聚合物缀合的硫酸化糖。 该方法包括向受试者施用包含与聚合物或硫酸化糖共轭的硫酸化糖的组合物。 硫酸化糖的分子量小于5000道尔顿。